A recently cleared phase 3 study (NCT06051409) will evaluate olverembatinib combined with chemotherapy as a first-line ...

Early results from the OLYMPIA-3 trial reveal odronextamab plus CHOP chemotherapy shows promising efficacy for untreated ...

The Olympia-3 study explores odronextamab as a promising chemo-free treatment for untreated diffuse B-cell lymphoma patients.

Long-term follow-up of the IMEG trial reveals potential survival benefits of a metal stent in low-risk MDS patients, ...

Exploring the impact of inflammation in MDS, this article highlights the need for novel therapies to enhance patient quality ...

A recent study highlights the benefits of early luspatercept treatment for patients with hemoglobin above 8, improving ...

A recent study reveals thrombocytopenia as a significant prognostic factor in low-risk MDS, impacting survival and treatment ...

A recent study highlights the effectiveness of Luspatercept in first-line treatment, showing significant patient benefits and ...

A recent study explores inflammatory profiles in low-risk MDS, revealing distinct patient categories and implications for ...

A recent post‑hoc analysis of the COMMANDS trial evaluated the benefits of Luspatercept versus Epoetin alfa (EA) in ESA‑naïve ...

Explore the latest trials on Eltrombopag and Eritacept, promising new treatments for low-risk MDS and CMML with TET2 ...

Discover how a metal statin offers a promising backup treatment for MDS patients, enhancing transfusion outcomes while ...